Total Raised

$65M

Investors Count

9

Funding, Valuation & Revenue

3 Fundings

PhaseV has raised $65M over 3 rounds.

PhaseV's latest funding round was a Series A for $50M on May 13, 2025.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

5/13/2025

Series A

$50M

$XXM

0

FY undefined

3

10/24/2023

Seed VC

$XXM

$XXM

0

FY undefined

10

Other Investors

$XXM

0

FY undefined

10

Date

5/13/2025

10/24/2023

Round

Series A

Seed VC

Other Investors

Amount

$50M

$XXM

Investors

Valuation

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

Sources

3

10

10

Start free trial
New call-to-action

PhaseV Investors

9 Investors

PhaseV has 9 investors. Viola Ventures invested in PhaseV's Series A funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

10/24/2023

5/13/2025

2
Seed VC, Series A (2025)

Venture Capital

Israel

00/00/0000

00/00/0000

LionBird

Subscribe to see more

Venture Capital

Israel

00/00/0000

00/00/0000

Exor Ventures

Subscribe to see more

Venture Capital

New York

00/00/0000

00/00/0000

Insight Partners

Subscribe to see more

Private Equity

New York

00/00/0000

00/00/0000

Accel

Subscribe to see more

Venture Capital

California

First funding

10/24/2023

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

5/13/2025

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

LionBird

Exor Ventures

Insight Partners

Accel

Rounds

2
Seed VC, Series A (2025)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Venture Capital

Private Equity

Venture Capital

Location

Israel

Israel

New York

New York

California

New call-to-action

Compare PhaseV to Competitors

Unlearn Logo
Unlearn

Unlearn focuses on artificial intelligence and digital twin technology within the clinical research sector. The company provides a platform that creates digital twins of clinical trial participants to predict outcomes and streamline the trial process. Unlearn's solutions aim to improve clinical trials by offering insights and decision support. It was founded in 2017 and is based in San Francisco, California.

Nova In Silico Logo
Nova In Silico

Nova In Silico specializes in the development of a clinical trial simulation platform within the biotechnology and pharmaceutical industry. Their main offering, jinkō, is a tool that streamlines clinical trials by using disease models and digital patients to predict clinical outcomes and optimize trial design. The platform is primarily utilized by biotech and pharma companies, academic research centers, and not-for-profit organizations to accelerate and de-risk the drug development process. It was founded in 2010 and is based in Lyon, France.

Terray Therapeutics Logo
Terray Therapeutics

Terray Therapeutics is a biotechnology company that focuses on the discovery and development of small molecule therapeutics. The company offers a platform that integrates ultra-high throughput experimentation with generative AI to improve drug discovery processes. Terray Therapeutics primarily serves the pharmaceutical and biotechnology sectors, using its platform to work with companies on various therapeutic targets. It was founded in 2018 and is based in Monrovia, California.

G
Galixir

Galixir is a biotech company engaged in the development, application, and promotion of artificial intelligence technology to develop new drugs. The company aims to support the research and development of both generic drugs and new drugs, develop artificial intelligence technology, optimize chemical synthesis pathways, and reduce drug manufacturing time and costs. The company was founded in 2019 and is based in Haidian, Beijing.

A
Acellera

Acellera is involved in drug discovery by integrating AI and quantum chemistry in the pharmaceutical and biotechnology sectors. The company's offerings include a platform for small-molecule discovery and potency optimization that utilizes quantum chemistry and AI/ML for lead candidate identification. The company serves the pharmaceutical and biotech industries. It was founded in 2006 and is based in Barcelona, Spain.

DEARGEN Logo
DEARGEN

DEARGEN is a pharmatech company that focuses on the drug discovery and development sector. The company offers a platform that integrates deep learning technology for genome data analysis, biomarker prediction, molecule selection, and lead optimization. The platform is used for discovering disease targets and developing small molecules for new drug design. It was founded in 2016 and is based in Daejeon, South Korea.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.